UAMS Myeloma Institute collaborates with Celgene Corporation and Dana-Farber Cancer Institute to Define Patient Segments for Targeted Therapy
The UAMS Myeloma Institute is collaborating with Celgene Corporation and Dana-Farber Cancer Institute in the creation of the Myeloma Genome Project, a landmark global initiative compiling the largest set of molecular profiling data with associated clinical outcomes data to develop a segmentation strategy that identifies specific molecular classifications of multiple myeloma.
The initiative eventually seeks to develop clinically relevant tests for genetic mutations that could improve the diagnosis, prognosis and treatment of patients with multiple myeloma around the globe.
Brian Walker, PhD, Director of Research, UAMS Myeloma Institute, first described the project at the 58th American Society of Hematology Annual Meeting:
“Pooling together multiple sets of high-quality genetic mutation data associated with clinical outcomes has provided a unique opportunity to develop a classification system at the molecular level to segment myeloma into a therapeutically meaningful subgroups.”
The Myeloma Genome Project has begun to integrate data sets collected not only from the UAMS Myeloma Institute, but also from the Myeloma XI trial (UK), Intergroupe Francophone du Myeloma/Dana-Farber Cancer Institute, and the Multiple Myeloma Research Foundation. Researchers are using this large set of diverse genomic data to identify genetic information that may identify clinical targets for therapy.
“The Myeloma Genome Project is a really exciting initiative that may change the way we manage myeloma patients.”
The Myeloma Genome Project intends to build a global network through expanded collaboration with myeloma centers around the world.